21.57
0.42 (1.99%)
| Previous Close | 21.15 |
| Open | 21.08 |
| Volume | 654,797 |
| Avg. Volume (3M) | 712,628 |
| Market Cap | 1,114,294,912 |
| Price / Earnings (Forward) | 94.34 |
| Price / Sales | 2.82 |
| Price / Book | 3.61 |
| 52 Weeks Range |
| Profit Margin | 17.92% |
| Operating Margin (TTM) | -9.46% |
| Diluted EPS (TTM) | 1.12 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 7.98% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 26.78 M |
| Levered Free Cash Flow (TTM) | 29.89 M |
| Return on Assets (TTM) | -5.20% |
| Return on Equity (TTM) | 19.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | CareDx, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 4.0 |
| Average | -0.50 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 3.22% |
| % Held by Institutions | 99.39% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |